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Background: Molecular diagnosis of Inherited Retinal Dystrophies (IRD) has long been challenging due to the
extensive clinical and genetic heterogeneity present in this group of disorders. Here, we describe the clinical
application of an integrated next-generation sequencing approach to determine the underlying genetic defects in
a Spanish family with a provisional clinical diagnosis of autosomal recessive Retinitis Pigmentosa (arRP).
Results: Exome sequencing of the index patient resulted in the identification of the homozygous BBS1 p.M390R
mutation. Sanger sequencing of additional members of the family showed lack of co-segregation of the p.M390R
variant in some individuals. Clinical reanalysis indicated co-ocurrence of two different phenotypes in the same family:
Bardet-Biedl syndrome in the individual harboring the BBS1 mutation and non-syndromic arRP in extended family
members. To identify possible causative mutations underlying arRP, we conducted disease-targeted gene sequencing
using a panel of 26 IRD genes. The in-house custom panel was validated using 18 DNA samples known to harbor
mutations in relevant genes. All variants were redetected, indicating a high mutation detection rate. This approach
allowed the identification of two novel heterozygous null mutations in RP1 (c.4582_4585delATCA; p.I1528Vfs*10 and
c.5962dupA; p.I1988Nfs*3) which co-segregated with the disease in arRP patients. Additionally, a mutational screening
in 96 patients of our cohort with genetically unresolved IRD revealed the presence of the c.5962dupA mutation in one
unrelated family.
Conclusions: The combination of molecular findings for RP1 and BBS1 genes through exome and gene panel
sequencing enabled us to explain the co-existence of two different retinal phenotypes in a family. The identification of
two novel variants in RP1 suggests that the use of panels containing the prevalent genes of a particular population,
together with an optimized data analysis pipeline, is an efficient and cost-effective approach that can be reliably
implemented into the routine diagnostic process of diverse inherited retinal disorders. Moreover, the identification of
these novel variants in two unrelated families supports the relatively high prevalence of RP1 mutations in Spanish
population and the role of private mutations for commonly mutated genes, while extending the mutational spectrum
of RP1.
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Genetic testing of inherited retinal dystrophies (IRDs) is
a highly complex and time-consuming process. More
than 200 genes have been associated with this heteroge-
neous group of disorders (RetNet, https://sph.uth.edu/
retnet/home.htm), characterized by the primary dysfunc-
tion or loss of photoreceptors leading to progressive vis-
ual impairment and blindness. Further complicating the
molecular diagnosis of IRDs, clinical diagnosis can also
be challenging due to IRD clinical features overlap. The
identification of causative mutations is important for
several reasons, among them, it allows geneticists to give
an adequate genetic counseling to the families, to estab-
lish genotype-phenotype correlations that predictably
improve the prognosis of the disease, and to monitor the
efficacy and safety of new therapeutic options.
Retinitis Pigmentosa (RP; MIM #268000) represents
the most prevalent clinical subtype of IRDs, affecting 1
in ~4,000 individuals. The clinical course of RP involves
progressive degeneration of rods and subsequent in-
volvement of cones as the disease progresses. To date,
more than 60 genes have been associated with RP, being
EYS the most prevalent gene worldwide [1-3]. Although
RP is usually manifested as a non-syndromic disease, it
can also be associated with a wide variety of extraocular
symptoms constituting syndromic forms of RP, being
Bardet-Biedl syndrome one of the most common (BBS;
MIM #209900). BBS is a model ciliopathy with high gen-
etic and clinical heterogeneity, generally inherited as an
autosomal recessive trait [4]. The estimated prevalence
in Europe is approximately 1/125,000 [5]. This disorder
is characterized by a combination of clinical symptoms
including obesity, RP, post-axial polydactyly, polycystic
kidneys and learning disabilities, some of which may ap-
pear many years after the onset of the disease. Clinical
expression is variable but many patients manifest most
of the clinical symptoms during the course of illness.
The number of causative genes is relatively high with 18
different genes associated so far (Ret Net; accessed 2014
Mar 1), including BBS1 (MIM #209901), that accounts
for approximately 40 % of BBS families.
One of the first RP-associated genes to be discovered
was RP1 (MIM #603937). This gene is located on chromo-
some 8q12 and consists of 4 exons [6]. It encodes
an oxygen-regulated photoreceptor protein with two
microtubule-binding, doublecortin-like domains (DCX)
at the N-terminus involved in microtubule stabilization.
Additionally, the C-terminal region has been implicated
in the binding of RP1 to proteins destined for the outer
segment [7]. Human RP1 specifically localizes to the
connecting cilia of rod and cone photoreceptors also
suggesting a role in the transport of proteins between
the inner and outer segments and/or in maintenance of
cilial structure [8]. The vast majority of pathogenicmutations in this gene are truncating variants clustered
in exon 4 (Human Gene Mutation Database, HGMD,
http://www.hgmd.cf.ac.uk/ac/index.php; accessed 2014
Mar 24). Mutations in RP1 can cause both autosomal
dominant (adRP) [9,10] or autosomal recessive RP
(arRP) [11-13], and although several mechanisms have
been suggested to explain the mutational mechanisms
in RP1 leading to dominant or recessive RP [14], no
clear models have been proposed.
The recently introduced next-generation sequencing
(NGS) technologies have greatly facilitated the molecular
diagnosis of IRD, in particular, in poorly defined or mis-
classified clinical cases [15]. At present, targeted analysis
of disease-specific candidate genes is most suitable for
diagnostic applications as it facilitates functional inter-
pretation of sequence variations and overcomes limita-
tions in computational analysis [16]. In this study, we
describe the successful application of an integrated NGS
strategy to provide an accurate clinical and molecular
diagnosis of concurrent BBS and arRP in a family provi-
sionally diagnosed of arRP. The definitive clinical diag-
nosis of the index patient was made based on clinical
re-examination and sequencing data generated through
whole-exome sequencing to identify the BBS1 p.M390R
mutation [17] responsible for the BBS phenotype. Like-
wise, disease-targeted gene sequencing resulted in the
identification of two novel truncating mutations in RP1
(p.I1528Vfs*10 and p.I1988Nfs*) in extended family
members affected of arRP.
Methods
Subjects and clinical assessment
Our study involved one Spanish family (RP368) native to a
small rural area with five affected members provisionally
diagnosed of arRP and four available healthy individuals
(Figure 1) recruited from the Ophthalmology Department
and derived to the Genetic, Reproduction and Fetal
Medicine Department. Clinical diagnosis of arRP was
established by ophthalmological examination as described
elsewhere [18]. For validation purposes of the IRD panel,
DNA samples of 18 IRD patients displaying different de-
grees of retinal degeneration and with known causal mu-
tations (Table 1) were included in the study. In addition, a
group of 200 matching control individuals and 96 IRD pa-
tients of our cohort without a molecular diagnosis were
also recruited. Written informed consent was obtained
from all participants. Also, expressed consent was signed
by all participants for the publication of their clinical data.
The study was reviewed and approved by the ethics com-
mittees of our institution and performed in accordance
with the tenets of the Declaration of Helsinki [19]. Periph-
eral blood was extracted for genomic DNA isolation from
leukocytes using the MagNA Pure LC system (Roche,
Indianapolis, IN) according to the manufacturer’s protocol.
Figure 1 Family cosegregation analysis. Pedigree showing segregation of the BBS1 and RP1 mutations. [M];[M]: Homozygous, [M];[=]:
Heterozygous, [=];[=]: Wild type, NA: Not available.
Table 1 IRD panel test samples
Samples Phenotype Gene Chr location Nt change Prot change Status Detection method Cvg mut
1 XLRP RPGR X:38145845 c.2405-2406delAG p.E802Gfs*32 HEMI WES 26
2 ARRP CRB1 1:197403836 c.2843G > A p.C948Y HOM Reseq 125
3 ARRP USH2A 1:215955412 c.10712C > T p.T3571M HET Asper 160
USH2A 1:216420460 c.2276G > T p.C759F HET Asper 70
4 USHER CDH23 10:73553078 c.6393delC p.I2132Sfs*11 HOM Asper 176
5 ARRP MERKT 2:112751826 c.1297-2A > G Splicing HOM Reseq 39
6 ARRP RDH12 14:68196055 c.806_810del5 p.A269Gfs*2 HOM Reseq 136
7 ARRP CNGA1 4:47954625 c.301C > T p.R101* HOM Reseq 19
8 ADRP RP1 8:55538471 c.2029C > T p.R677* HET Asper 247
9 ADRP PRPF3 1:150316692 c.1481C > T p.T494M HET Asper 35
10 XLRP RP2 X:46713107 c.299dupT p.F101Vfs*23 HEMI Sanger 24
11 STGD ABCA4 1:94506901 c.3386G > T p. R1129L HET Asper 24
ABCA4 1:94508434 c.3210_3211insGT p.S1071Vfs*14 HET Asper 24
12 ARRP NR2E3 15:72105913 c.932G > A p.R311Q HOM Reseq 28
RDH12 14:68195950 c.701G > A p.R234H HET Reseq 51
13 ARRP RHO 3:129252539 c.1025C > T p.T342M HOM Reseq 29
14 ADRP PRPH2 6:42672285 c.646C > T p.P216S HET Asper 45
15 USHER MYO7A 11:76867944 c.626C > A p.S210* HOM Asper 16
16 ADRP RHO 3:129251107 c.544G > A p.G182S HET Reseq 31
17 ARRP EYS 6:64776240 c.6714delT p.I2239Sfs*17 HOM Sanger 13
18 ARRP CERKL 2:182423344 c.769C > T p.Arg257* HOM Asper 73
WES: Whole Exome Sequencing; Reseq: Custom genome resequencing microarray; Asper: commercially available microarray analysis (Asper Biotech);
Sanger: Sanger sequencing.
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were processed for WES while DNA samples from 18 pa-
tients with previously identified mutations and from indi-
vidual II:5 were processed for gene panel sequencing.
Previous molecular genetic analysis
The index patient was first analyzed and excluded for
known mutations in arRP genes by applying commer-
cially available microarray analysis (Asper Biotech, Tartu,
Estonia), a custom genome resequencing microarray [20]
and by direct sequencing of EYS [2]. Causative muta-
tions of the IRD panel validation samples were previ-
ously identified by different strategies (Table 1).
Whole-exome sequencing and data analysis
Library preparation and exome capture were performed
using NimbleGen SeqCap EZ Exome libraries V3 (Roche
NimbleGen, Inc., Madison, WI, USA) and sequenced on
a SOLiD 5500xl platform. These procedures and theTable 2 List of genes included in the capture IRD panel



























RP: Retinitis pigmentosa; AD: Autosomal dominant; AR: Autosomal recessive; XL: X-l
MD: Macular degeneration; CSNB: Congenital stationary night blindness; USH: Usheanalysis of data from deep sequencing were carried out
as previously described [18,21].
Design of the capture IRD panel
We developed a capture panel of 26 retinal disease genes
commonly mutated in our population (Table 2). Coding
exons plus 25 bp of intronic flanking sequence of targeted
genes and their genomic coordinates were identified using
UCSC Genome Browser (http://genome.ucsc.edu/) and
submitted to Roche NimbleGen (Madison, WI) to gener-
ate a SeqCap EZ Choice Library of hybridization probes.
The probes covered a total of 510 exons and the entire
custom design spanned 118,238 bp. The final capture size
was 248,054 bp.
DNA library preparation and targeted sequencing
Library preparation was performed according to the man-
ufacturer’s protocol (GS FLX Titanium Rapid Library
Preparation Method Manual, January 2010 version).uence Exons Pathology
50 ADRP, ARRP, ARCRD, ARMD, STGD







49 USH, Deafness alone or syndromic
8 ADRP, ARRP, ARESCS
22 ARRP, ADCSNB
28 ARRP, ADCRD, ADMD
16 ADRP
14 ADRP
3 ADRP, ADMD, ADCRD and digenic
9 ADRP, ARLCA










inked; LCA: Leber congenital amaurosis; CRD: Cone or cone-rod dystrophy;
r syndrome; STGD: Stargardt disease; ESCS: Enhanced S-cone syndrome.
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nebulization resulting in a majority of fragments between
600-900 bp. Fragments were end repaired, ligated to the
provided adaptors and eluted in water following small
fragments removal using AMPure Beads (Beckman
Coulter, Agencourt, Beverly, MA). The library was ampli-
fied for 12 cycles by pre-capture ligation-mediated PCR
(LM-PCR) using FastStart High Fidelity PCR System
(Roche, Basel, Switzerland) and specific primers for the
adaptors. After purification, 1 μg of LM-PCR product was
hybridized to the custom designed SeqCap EZ Library of
biotinylated probes for 72 h at 47°C. Captured DNA frag-
ments were purified with streptavidin-conjugated mag-
netic beads (Invitrogen, Carlsbad, CA, USA) and washed.
Amplification was performed for 15 cycles by post-
capture LM-PCR using FastStart High Fidelity PCR
System. The final concentration of each captured li-
brary was measured with Quant-iT PicoGreen dsDNA
Assay Kit (Invitrogen, Carlsbad, CA) and diluted to 106
molecules/μl. Emulsion PCR was performed according
to the manufacturer’s instructions (emPCR Amplification
Method Manual-Lib-L, GS Junior Titanium Series, March
2012). To perform the emPCR an input of 0.7 molecules
per bead was chosen. After enrichment, about 500,000
beads were sequenced on 454 Roche GS Junior sequencerFigure 2 Pipeline designed for data analysis. Bioinformatic analysis inclu
by a pathogenicity analysis in which the candidate variants (CV) are prioriti
inform the patient. A reanalysis of regions with low coverage and WES willaccording to the manufacturer’s protocol (Sequencing
Method Manual GS Junior, Titanium Series, March 2012).
Bioinformatics analysis
An analysis pipeline was developed to identify pathogenic
mutations (Figure 2). After duplicates removal, reads were
aligned against the human genome reference (hg19) using
the GS Reference Mapper software (Roche, version 2.7).
Improperly mapped reads were filtered out with the SAM-
tools package, which was also used to generate, sort and
index BAM files. To analyze the coverage and the percent-
age of reads on target we used the BEDtools package.
Variant calling was performed with the software GATK
(Genome Analysis Toolkit, version 1.4) [22] to detect
SNVs, while indels were called with FreeBayes software
(version 0.9.10) (https://github.com/ekg/freebayes). To
avoid artifacts, variants with a coverage <6X, a percentage
of total reads supporting the variant allele <25%, and vari-
ants with a disequilibrium (<15%) between number of for-
ward and reverse sequences were removed. In addition, an
in-house developed database of common variations in our
cohort was use to eliminate those variants that appeared
in more than two patients. Sequence variants annotation
was performed using Variant Tools [23]. Annotated vari-
ants located in non-coding regions outside of the spliceding mapping, calling, filtering, and annotation of variants, followed
zed and validated with the aim of finding the causal mutation and
be conducted when no candidate variants (NCV) are identified.
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nology Information (NCBI) Single Nucleotide Polymorph-
ism database (dbSNP, http://www.ncbi.nlm.nih.gov/SNP/)
and 1000 Genomes project (http://www.1000genomes.
org/) database, with a MAF higher than 0.01 were dis-
carded. The remaining variants were compared with
human mutation databases such as HGMD and ClinVar
(http://www.ncbi.nlm.nih.gov/clinvar/) to detect known
disease-associated mutations, using the TEAM tool
(http://team.babelomics.org) with a definition of the
panel described in Table 2. Sequence variants were fur-
ther prioritized according to inheritance patterns and
type of mutations using the BiERapp tool, generating a
list of candidate causal mutations (http://bierapp.babe-
lomics.org).
Verification and determination of the pathogenicity of
variants
Predicted disease-causing variants were confirmed by
Sanger sequencing using specific primers designed by
Primer3 software (http://bioinfo.ut.ee/primer3-0.4.0/)
and co-segregated in available family members DNA
samples. Novel variants were subsequently screened in
200 healthy matched control subjects by Sanger se-
quencing and in Exome Variant Server (http://evs.gs.
washington.edu/EVS/). The pathogenicity of novel mis-
sense substitutions was evaluated using Polymorphism
Phenotyping v2 (PolyPhen-2, http://genetics.bwh.har-
vard.edu/pph2/) and Sorting Intolerant From Tolerant
(SIFT, (http://sift.bii.a-star.edu.sg) scores. The correct
name of the variation according to the Human Genome
Variation Society (http://www.hgvs.org) nomenclature
guidelines was checked using Mutalyzer (http://www.
LOVD.nl/mutalyzer).
Microsatellite marker analysis
Microsatellite marker analysis was carried out in available
family members DNA samples of the arRP branch. For
this purpose, a total of five microsatellite markers flanking
RP1 were selected from UCSC Genome Browser. PCR
amplification using genomic DNA samples and primers
closely flanking the region containing microsatellite re-
peats were used for analysis (Additional file 1). PCR prod-
ucts were genotyped using an ABI-3730 sequencer
(Applied Biosystems, USA), and analyzed by GeneMapper
v.4.0 software (Applied Biosystems).
Mutational screening of RP1 in additional IRD patients
To detect additional cases carrying the novel RP1 muta-
tions, we performed Sanger sequencing in 96 IRD pa-
tients of our cohort without a genetic diagnosis. This
study group consisted of 75 cases clinically diagnosed of
arRP, 3 of adRP, 3 of cone-rod dystrophies, 6 of Leber
Congenital Amaurosis, and 9 of Stargardt disease.Results
WES and clinical refinements
The index patient (IV:2) (Figure 1) had received a
provisional diagnosis of arRP based on previous family
history (II:1, II:5, II:9 and III:8) with clinical manifestations
typical of a severe form of RP characterized by early age of
onset and a rapid progression of the disease, leading to a
total blindness before age 30 in most patients. The first
symptom of the index patient was night blindness at age
of six, followed by decreased visual acuity, reduced visual
field, dyschromatopsia and photophobia. The fundus
examination showed signs of RP such as bone spicule
pigmentation and attenuation of the retinal vessels.
In order to identify causal mutations, we sequenced the
exomes of the index patient, one healthy sibling (IV:1) and
both unaffected parents (III:1 and III:2). This allowed the
identification of the known homozygous p.M390R muta-
tion in the BBS-associated gene BBS1, previously reported
by Mykytyn et al, [17]. Lack of segregation of this variant
in extended family members prompted us to clinically re-
evaluate the entire family focusing on the identification of
extraocular symptoms associated with BBS. We found that
the index patient showed characteristic BBS features in-
cluding obesity, learning disabilities and postaxial polydac-
tyly, resulting in a clinical reclassification of this family
branch from arRP to BBS. In contrast, fundus examination
in the rest of affected members showed typical signs of RP
with pale optic nerve disc, retinal vessels attenuation and
bone spicule pigmentation in the periphery, confirming a
diagnosis of non-syndromic arRP in individuals II:5, II:9
and III:8. Therefore, the causal mutation of this family
branch remained to be discovered.
Given that individual II:1 was also affected of arRP, we
hypothesized that patient III:1 must be an obligate car-
rier of one of the arRP mutations. To assess this possi-
bility, a screening of heterozygous mutations in known
RP genes present in the WES data of individual III:1 was
carried out as a first approach to detect the cause of the
disease in the arRP members, but no candidates were
found.
Validation of the customized IRD panel
The genetic cause of arRP was studied by sequencing 26
IRD genes. In order to assess the reliability of our capture
panel as a diagnostic tool, we tested 18 samples with
known causative variants on exons or bordering se-
quences in 17 retinal disease genes included in the panel.
A total of 21 mutations were checked, 6 indels and 15
SNVs.
Data quality
For each sample, gene panel sequencing generated an
average of data output of 56 Mb and 134,656 reads per
run with a mean length of 416 bp. The mean coverage
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with 72% of reads covered >20x and 93% >6x (Figure 3B).
On average, 98% of targeted bases were covered indicating
that the coverage was sufficiently high for sensitive detec-
tion of variants. The specific coverage for the 21 checked
mutations is shown in Table 1. Furthermore, the mean
coverage for the 26 targeted genes ranged between 36x
(RPGR) and 159x (RP1) (Figure 3C). The mean percentage
of reads mapped on target was 55%, while up to 70% of se-
quences overlapped the targeted region. However, only 4
samples showed a percentage of reads on target lower
than 50% (samples #10, #11, #13, and #18), achieving most
samples a ratio greater than 60%.Detection, filtering, and verification of variants
On average, targeted sequencing of validation samples
revealed 2,318 variants per patient (616 SNVs and 1,702
indels). The filtering of variants was performed as de-
tailed in Materials and Methods and resulted in a mean
of 48 variants per sample. After comparing with human
mutation databases HGMD and ClinVar, a mean of 2 re-
ported variants were identified for each sample, among
which the causative mutation was found in 14 cases.
The prioritizing step left 1-2 candidate variants per sam-
ple to be validated. After validation, 22 variants were
considered possible causative mutations, of which 21
matched the causal mutations previously identified, and
only one additional novel mutation in RP1 in sample #8
was found (c.3956A > G, p.E1319G). Therefore, all vari-
ants were properly redetected using this NGS approach
and verification of underrepresented NGS regions by
Sanger sequencing was not required in this study.Identification of pathogenic mutations
To identify causative mutations of non-syndromic arRP in
family RP368, the specific IRD panel was used to predict
potential pathogenic variants in patient II:5. This sample
showed a mean coverage of 32x, with the 99.5% of tar-
geted bases covered and a percentage of reads on target
of 50%. Application of the previously described auto-
matic variant calling, filtering, and annotation pipeline
of the capture sequencing data from this patient detected
two heterozygous variants located on exon 4 of RP1
(c.4582_4585delATCA; p.Ile1528Valfs*10 and c.5962dupA;
p.Ile1988Asnfs*3) (Figure 4), with an specific coverage of
111x and 87x, respectively. The two mutations were
confirmed by Sanger sequencing and cosegregation in
available arRP family members. Both mutations were
novel and had never been reported in public variant da-
tabases such as dbSNP, EVS or 1000 genomes database.
Additionally, we did not detect such changes in 200
control individuals. These novel frameshift mutations
(p.Ile1528Valfs*10 and p.Ile1988Asnfs*3) resulted inpremature termination codons, causing a truncated RP1
protein in both cases. Thus, the compound heterozygosity
for these mutations was proposed as the most probable
disease-causing mechanism in the arRP members.
To discard the possibility that the two mutations were
located on the same allele, we performed a linkage ana-
lysis using five microsatellite markers flanking the RP1
gene on individuals II:5, II:7, II:9 y III:8. The haplotypes
confirmed that each mutation is found in different al-
leles (Additional file 2).
Mutational screening of RP1 mutations in unresolved IRD
cases
Direct full sequencing of the two novel RP1 mutations in
96 IRD patients without a molecular diagnosis allowed the
detection of the c.5962dupA mutation in homozygosity in
one additional family of our cohort (Additional file 3).
This family was not related to family RP368. Clinically, pa-
tient with homozygous mutation c.5962dupA showed
signs of typical early onset RP and resembles arRP affected
members of family RP368.
Discussion
Clinical and genetic complexity of IRD makes the accurate
diagnosis of some cases only accessible by NGS ap-
proaches. Here, we followed a strategy that combines ex-
ome and disease-targeted gene panel sequencing to assist
in the molecular diagnosis of a family affected of both
BBS and RP. Whole exome sequencing allowed the identi-
fication of the BBS1 p.M390R mutation as the BBS-
causing variant while the genetic cause of non-syndromic
arRP was assessed by gene panel sequencing.
Compared to exome sequencing, targeting fewer genes
has clear advantages including the analysis of more patient
samples per instrument cycle, a greater depth of coverage,
a simplified data interpretation and less restrictive ethics.
Validation of our disease-targeted gene panel was critical
to ensure high quality interpretation of clinical evidences.
All types of variants were detected by this platform indi-
cating a high specificity of mutation detection. Of note,
the identification of the c.2405_2406delAG variant located
in the hot spot exon ORF15 of RPGR, a domain that usu-
ally remains problematic for sequencing, indicated that
the enrichment technology produced suitable calls for use
in clinical laboratories.
Analysis of our NGS data also resulted in the identifi-
cation of definite candidate variants for each test sample
with the exception of validation sample #8, harboring
not only the causal adRP mutation p.R677* in RP1, but
also an additional variant (p.E1319G). The fact that the
vast majority of pathogenic mutations in RP1 result in
premature stop codons (nonsense and frameshift muta-
tions) indicate that the most probable adRP-causative
mutations in validation sample #8 is p.R667* and not p.
Figure 3 Coverage analysis of 454 pyrosequencing data of the 18 samples used for IRD panel validation. (A) Mean coverage of the
targeted regions for each individual. (B) Percentage of targeted positions covered less than 6x (gray), between 6x and 20x (white), and more than
20x (black), for each individual. (C) Mean coverage for each targeted gene.
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Figure 4 Schematic representation of the novel RP1 mutations. (A) Overview of chromosome 8. RP1 is mapped on region 8q12.1 (green
bar). (B) Gene structure of RP1 gene containing 4 exons. The position of identified variants is stated with a broken line. Coding exons are shown
as filled boxes while unfilled boxes reflect UTRs. (C) Electropherograms of patient II:5 showing the heterozygous mutations in exon 4 of RP1 gene.
(D) RP1 protein representation with two doublecortin domains (DCX) marked in green, and the location of variants indicated by a broken line.
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simply reflect the high frequency of carriers harboring
heterozygous mutant alleles of IRD genes in the general
population [24]. Additionally, the p.R677* mutation has
been reported as the most frequently pathogenic RP1
mutation [14,25] with a location consistent with a dom-
inant inheritance pattern [12].
Studies performed after this panel design have shown
that, of all solved cases in our cohort, 98% of families
carry mutations in one of the genes included in the
panel while 2% of cases harbor mutations in other genes
(unpublished data), indicating that, as expected, we pri-
marily find novel mutations in prevalent genes in our
population. Therefore, although we did not aimed at
evaluating the diagnostic yield in this study, we can expect
that a large proportion of pending cases may be solved
using this panel which is remarkable given the small target
size compared to other IRD panels [15,26-29]. Nonethe-
less, we are aware that to increase the diagnostic yield of
the panel, the analysis of other types of variants such as
large CNVs or structural variants must be considered [30].
Also, genes newly found to be mutated in our cohort as
well as non-coding regions with previously reported deep-
intronic pathogenic mutations [31-33] must be included.
The implementation of this tool for the molecular diag-
nosis of arRP individuals resulted in the reliable identifica-
tion of two novel RP1 mutations (c.4582_4585delATCA;
p.Ile1528Valfs*10 and c.5962dupA; p.Ile1988Asnfs*3).
Family segregation showed indeed the presence of the
variant c.5962dupA in heterozygous state in individual
III:1. However, this variant was filtered out during there-analysis of the WES data of heterozygous variants in
RP genes in this individual due to low coverage (4x),
supporting the use of gene panels to increase the cover-
age of certain target regions.
Screening of our cohort for these mutations led to the
molecular diagnosis of an unrelated arRP family carrying
the c.5962dupA variant in homozygosis. The presence of
this variant in two unrelated families of our cohort
seems to indicate the recurrent nature of this novel vari-
ant in Spanish population. These data are in agreement
with a recent report showing that the contribution of
RP1 to arRP in the Spanish population may have been
underestimated [13].
It has been previously hypothesized that the specific
location of mutations in RP1 may be an important factor
in determining their functional effect [7]. Given that
both frameshift mutations found in this study are lo-
cated in the second half of exon 4, the mutated mRNA
would not be theoretically susceptible to the nonsense-
mediated decay (NMD) pathway [34], resulting in pre-
maturely truncated proteins. It has been proposed that
while larger disruptions of RP1 are often associated with
adRP due to deleterious effects of the truncated proteins,
the lack of only the most terminal portion results in a
loss of RP1 function, causing arRP [7,12]. This would ex-
plain that the two novel detected mutations are patho-
genic in compound heterozygosity or homozygosity,
while heterozygous carriers of only one of them are
asymptomatic. Besides their location, the type of muta-
tion appears to be also important to the etiopathogenesis
of RP associated with RP1 mutations. Both families
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with severe RP, characterized by early age of onset and a
rapid progression of the disease. These clinical charac-
teristics are consistent with previous studies [11,13] de-
scribing that patients with arRP due to RP1 mutations
show severe RP and present equivalent phenotypes in
different families.
Previous reports have shown other cases of apparent
clinical heterogeneity due to independent segregation of
two different retinal phenotypes secondary to mutations
in two different genes [35,36]. Interestingly, other cases
of concurrent retinal disorders have been explained by
the presence of p.M390R and mutations in the arRP-
associated genes C2ORF71 and RP1 [37,38]. In this study
we further highlight how isolated population or consan-
guinity could increase the risk factor of developing diverse
IRDs in the same family. Consequently, it is important to
consider the existence of different genetic causes in the
same family when clinical manifestations and genetic data
do not correlate.
Conclusions
The genetic findings for RP1 and BBS1 genes revealed
co-occurrence of two distinct retinal phenotypes result-
ing in the accurate diagnosis of a poorly defined clinical
case. The detection of two novel pathogenic RP1 variants
p.Ile1528Valfs*10 and p.Ile1988Asnfs*3 suggests that the
use of IRD panels of a small size, limited to prevalent
genes of a particular population, together with an opti-
mized data analysis pipeline, is an efficient and cost-
effective approach for the diagnosis of diverse retinal
disorders. Moreover, the implementation of this panel
as a diagnostic tool can be useful to determine the
prevalence of known IRD genes in our cohort. In fact,
the identification of RP1 mutations in two unrelated
families supports the relatively high prevalence of this
gene in Spanish population.
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